GET DAILY SIGNALSPerspective Therapeutics (CATX) Stock Plunges -67% Over 30 Days After Mixed Trial Results
Key Takeaways
- Perspective Therapeutics (CATX) shares declined roughly 67% over the trailing 30 days, extending a steeper multi-month downtrend.
- The selloff was triggered by an October 2026 Phase 1/2a data readout for its lead candidate, VMT-α-NET, which investors viewed as mixed.
- Analysts responded with rating and price-target cuts, including a downgrade from RBC Capital and lowered targets from Piper Sandler, Truist, and Wedbush.
- Third-quarter 2026 results reported in early November came in below consensus, adding to the pressure.
- The company maintains a cash runway extending into 2028 and received Fast Track designation for its PSV359 candidate.
- Investors can explore additional detail on Price Targets, Earnings, and Forecast for CATX.
Perspective Therapeutics and Its Position in Radiopharmaceuticals
Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company based in Seattle, Washington, that develops precision targeted alpha therapies (TATs) for the treatment of cancer. Its platform uses the alpha-emitting isotope lead-212 (²¹²Pb) to deliver radiation directly to tumor cells through specialized targeting molecules. The company's lead candidate, VMT-α-NET (bamzireotide navoxetan), is in Phase 1/2a development for somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors. Additional programs include VMT01 for MC1R-positive metastatic melanoma and PSV359, a fibroblast activation protein (FAP)-targeting therapy. The company, formerly known as Isoray, Inc., trades on the NYSE American exchange and is followed closely by investors for its differentiated approach within the fast-growing radiopharmaceutical sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CATX Stock Performance: Last 30 Days Compared to the Quarter
Over the trailing 30 days, CATX shares fell from a closing level near $2.52 in mid-October to roughly $0.83 in recent trading, a decline of approximately 67%. The drop was abrupt rather than gradual: shares fell sharply in a single session in late October after a clinical data presentation, then continued to slide through early November alongside analyst revisions and quarterly results.
The quarterly trend is even more pronounced. Three months earlier, the stock traded around $3.18, meaning the trailing-quarter decline totals roughly 74%. The stock has approached levels near its 52-week low, reflecting sustained selling pressure across both the short-term and medium-term timeframes.
Factors Behind the Recent 30-Day Move in CATX
The primary catalyst was a clinical update. In late October 2026, Perspective Therapeutics presented interim Phase 1/2a data for VMT-α-NET at the ESMO conference. The results showed durable disease control across dose cohorts and a reported 72% progression-free survival at 18 months, but the efficacy profile came in somewhat below some investors' expectations, and a limited number of renal events were noted. The shares fell about 29% in the following session.
That move was reinforced by analyst actions. RBC Capital downgraded the stock to Sector Perform from Outperform and cut its price target to $4 from $14, citing the updated trial data and execution risks. In early November, third-quarter results also disappointed: the company reported an adjusted loss per share of $0.27 versus a consensus estimate of $0.25 and revenue below expectations. Following the report, Piper Sandler lowered its target to $8 from $14, Truist to $8 from $11, and Wedbush to $7 from $9, though those firms retained positive ratings.
Broader Pressures Over the Past Quarter
The broader three-month decline reflects a confluence of factors beyond any single data point. Radiopharmaceutical developers have faced volatile sentiment as investors weigh clinical durability against competitive positioning and capital needs. Perspective Therapeutics also remains a pre-revenue, clinical-stage company, so concerns about future financing and potential dilution weigh on the shares; at least one analyst cited adjustments to capital-raise assumptions in revising its target. Positive developments, including Fast Track designation for PSV359 and data presentations at the SITC and NANETS conferences, provided intermittent support but were not enough to offset the broader downward trend. The result has been a stock that continued to drift lower even after the initial data-driven drop. From what I see, this highlights the challenges for clinical-stage names in this space.
Key Drivers to Monitor for CATX Going Forward
Several upcoming factors could shape CATX's trajectory. Management has reaffirmed a goal of holding an End-of-Phase 2 meeting in the first quarter of 2027 for VMT-α-NET, and alignment with the FDA on dose, patient population, and Phase 3 trial design is widely viewed as a critical next step. Additional follow-up data for the VMT01 melanoma program is expected through mid-2027, and a clinical update for PSV359 is anticipated in 2027. Investors will also monitor the competitive radiopharmaceutical landscape, manufacturing expansion progress, and the company's balance sheet, including how long its cash runway lasts and whether future financing becomes necessary. Analyst views remain divided, with price targets spanning a wide range, underscoring the uncertainty around the company's clinical and commercial path. I’m watching this closely as the next data points could provide more clarity.
Using Tickeron AI Tools for Deeper Analysis
I often turn to Tickeron’s automated tools when evaluating names like this one, particularly to review performance across different market conditions and compare signals. The Trending AI Robots section offers a focused look at top-performing bots that handle a range of strategies and timeframes, which can be useful for identifying systematic approaches without manual screening. It is a practical way to supplement fundamental research with data-driven insights.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CATX sees MACD Histogram just turned negative
CATX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 42 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CATX as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CATX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CATX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where CATX advanced for three days, in 211 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CATX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.296) is normal, around the industry mean (4.142). P/E Ratio (-0.632) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CATX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CATX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of therapeutic radioactive isotopes
Industry MedicalNursingServices
Advertisement